To read the full story, subscribe or sign in.

Xuanzhu Pharma acquires Combio in bid to expand biologics pipeline

Feb. 9, 2021

HONG KONG – Xuanzhu Biopharmaceutical Co. Ltd., a subsidiary of Beijing-based Sihuan Pharmaceutical Holdings Group Ltd., has acquired antibody technology firm Beijing Combio Pharmaceutical for an undisclosed amount.

BioWorld Asia Deals and M&A Bispecific antibody China

Today's news in brief

BioWorld

BioWorld briefs for July 7, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for July 7, 2025.

House passes H.R. 1, restoring R&D tax cuts

BioWorld MedTech

The House of Representatives passed H.R. 1, also known as One Big Beautiful Bill, which will restore personal income tax cuts that expired in 2022. However, the...

3D rendering of a molecular glue mediating the interaction between two proteins

With surface mimicry, molecular glues shed hairpin need

BioWorld Science

Degradation is a therapeutic strategy that could offer possibilities to get at currently undruggable target proteins. In targeted degradation, compounds induce...

Illustration of the β2-adrenergic receptor

Exercise-mimicking compound offers alternative to GLP-1 therapies

BioWorld

An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...